Trulieve Cannabis (TCNNF) Non-Current Deferred Tax Liability (2020 - 2026)
Trulieve Cannabis (TCNNF) recorded quarterly Non-Current Deferred Tax Liability of $169.8 million in Q1 2026, down 4.61% quarter-over-quarter from $178.0 million in Q4 2025, and down 11.53% on a YoY basis from $191.9 million in Q1 2025.
Trulieve Cannabis (TCNNF) Non-Current Deferred Tax Liability (2020 - 2026) Analysis & Trends
Trulieve Cannabis' Non-Current Deferred Tax Liability history runs 7 years deep, the most recent figure standing at $169.8 million for Q1 2026.
- In Q1 2026, Non-Current Deferred Tax Liability fell 11.53% year-over-year to $169.8 million; the TTM figure through Mar 2026 stood at $169.8 million (down 11.53% YoY), while the FY2025 annual figure was $178.0 million, down 9.44% from the prior year.
- Non-Current Deferred Tax Liability was $169.8 million for Q1 2026 at Trulieve Cannabis, down from $178.0 million in the prior quarter.
- In the past five years, Non-Current Deferred Tax Liability ranged from a high of $243.4 million in Q1 2022 to a low of $169.8 million in Q1 2026.
- Historically, Non-Current Deferred Tax Liability has averaged $206.1 million across 5 years, with a median of $207.0 million in 2023.
- The sharpest annual moves came in 2022 and 2025: Non-Current Deferred Tax Liability jumped 1001.88% in 2022, then declined 11.59% in 2025.
- A 5-year view of Non-Current Deferred Tax Liability shows it stood at $224.9 million in 2022, then declined by 7.98% to $207.0 million in 2023, then fell by 5.03% to $196.5 million in 2024, then fell by 9.44% to $178.0 million in 2025, then declined by 4.61% to $169.8 million in 2026.
- The last three Non-Current Deferred Tax Liability figures came in at $169.8 million (Q1 2026), $178.0 million (Q4 2025), and $181.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn |
| 10 | Trulieve Cannabis | - | - | 170.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 169.78 Mn |
| Mar 31, 2026 | 169.78 Mn |
| Dec 31, 2025 | 177.99 Mn |
| Dec 31, 2025 | 177.99 Mn |
| Sep 30, 2025 | 181.88 Mn |
| Sep 30, 2025 | 181.88 Mn |
| Jun 30, 2025 | 186.63 Mn |
| Jun 30, 2025 | 186.63 Mn |
| Mar 31, 2025 | 191.90 Mn |
| Mar 31, 2025 | 191.90 Mn |
| Dec 31, 2024 | 196.55 Mn |
| Dec 31, 2024 | 196.55 Mn |
| Sep 30, 2024 | 204.24 Mn |
| Sep 30, 2024 | 204.24 Mn |
| Jun 30, 2024 | 211.09 Mn |
| Jun 30, 2024 | 211.09 Mn |
| Mar 31, 2024 | 216.98 Mn |
| Mar 31, 2024 | 216.98 Mn |
| Dec 31, 2023 | 206.96 Mn |
| Dec 31, 2023 | 206.96 Mn |